Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Príomhchruthaitheoir: | Leng, H |
---|---|
Rannpháirtithe: | Simon, K |
Formáid: | Tráchtas |
Teanga: | English |
Foilsithe / Cruthaithe: |
2019
|
Ábhair: |
Míreanna comhchosúla
Míreanna comhchosúla
-
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
de réir: Mabilleau, G, et al.
Foilsithe / Cruthaithe: (2009) -
Stimulation of osteoclast formation by inflammatory synovial fluid
de réir: Adamopoulos, I, et al.
Foilsithe / Cruthaithe: (2006) -
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
de réir: Mabilleau, G, et al.
Foilsithe / Cruthaithe: (2008) -
Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease
de réir: Magetsari, Rahadyan, et al.
Foilsithe / Cruthaithe: (2022) -
Maintenance therapy in multiple myeloma
de réir: Jean-Luc Harousseau
Foilsithe / Cruthaithe: (2009-08-01)